influenza
virus
highli
contagi
pathogen
associ
yearround
global
record
reach
nearli
million
morbid
halfamillion
mortal
four
type
influenza
virus
ie
b
c
identifi
influenza
virus
c
isol
pig
human
isol
cattl
less
common
typic
influenza
viru
c
associ
less
sever
ill
hand
influenza
virus
infect
avian
mammal
includ
human
b
almost
exclus
infect
human
seal
account
annual
global
burden
influenza
persist
influenza
virus
b
attribut
abil
evolv
rapidli
antigen
variabl
also
common
influenza
virus
b
partli
result
phenomenon
call
antigen
drift
refer
amino
acid
chang
allow
viral
escap
neutral
antibodi
immuneescap
mutant
often
tend
higher
hostcel
avid
compar
wildtyp
viru
expos
vaccin
host
viceversa
host
studi
fergusson
et
al
reveal
antigen
drift
season
influenza
virus
b
estim
fixat
rate
nucleotid
substitut
per
site
per
year
respect
support
idea
antigen
drift
occur
frequent
influenza
virus
influenza
b
virus
addit
high
mutat
rate
caus
tremend
impact
efficaci
season
influenza
vaccin
compris
forecast
strain
instanc
gain
loss
nlink
glycosyl
site
hemagglutinin
ha
also
particip
antigen
drift
skehel
et
al
show
singl
substitut
creat
novel
nglycosyl
site
allow
antigen
variant
escap
neutral
monoclon
antibodi
studi
author
observ
influenza
epidem
strain
known
glycosyl
site
also
recogn
unglycosyl
antibodi
rais
virus
two
earlier
epidem
illustr
alter
glycosyl
pattern
one
mean
use
virus
result
potenti
caus
vaccin
failur
antigen
shift
also
allow
influenza
virus
escap
preexist
immun
mechan
reliant
abil
eight
genom
fragment
influenza
virus
reassort
genom
influenza
viral
subtyp
occur
two
distinct
virus
infect
common
host
gener
novel
viral
subtyp
strain
thu
antigen
shift
princip
underli
influenza
viru
pandem
antigen
drift
underli
vaccin
mismatch
season
influenza
b
virus
wide
hostrang
influenza
virus
contribut
recur
case
influenza
year
round
furthermor
antigen
drift
shift
particularli
reason
immedi
need
highli
efficaci
intervent
review
vital
influenza
manag
strategi
novel
vaccin
antivir
develop
approach
deliber
prospect
three
type
vaccin
influenza
current
use
worldwid
includ
inactiv
influenza
vaccin
iiv
liveattenu
influenza
vaccin
laiv
influenza
viru
subunit
vaccin
advantag
drawback
iiv
formul
replicationincompet
viru
due
whole
pathogen
inactiv
usual
achiev
formaldehyd
treatment
split
virion
vaccin
gener
disrupt
viral
membran
intramuscular
administr
iiv
shown
induc
local
system
immun
howev
maintain
antibodi
titer
booster
vaccin
requir
addit
consider
vaccin
efficaci
rais
follow
metadata
analysi
suggest
children
protect
influenza
percentag
go
bit
higher
adult
laiv
compris
reassort
virus
gener
coldadapt
donor
virus
contribut
intern
gene
identifi
virul
circul
strain
virus
contribut
ha
neuraminidas
na
recommend
coldadapt
donor
virus
rais
sever
passag
embryon
chicken
egg
gradual
reduct
temperatur
everi
round
passag
process
reassort
virus
compris
laiv
grow
temperatur
rang
cell
line
mucos
surfac
nasopharynx
administ
intranas
replic
laiv
virus
nasopharynx
elicit
immun
respons
epitom
natur
influenza
infect
reason
laiv
shown
superior
iiv
term
induct
mucos
immun
via
secret
immunoglobulin
use
laiv
proven
safe
children
month
immunocompromis
person
hivinfect
chronic
bronchiti
cystic
fibrosi
speltout
advantag
noninvas
capac
attenu
virus
made
suitabl
use
categori
vaccin
although
laiv
recommend
peopl
underli
chronic
medic
condit
typic
setback
use
laiv
possibl
attenu
viru
undergo
genet
modif
consequ
revert
virul
case
report
laiv
furthermor
sinc
vaccin
virus
grown
egg
sever
concern
allerg
reaction
among
certain
vaccin
wherea
laiv
ovalbumin
content
respons
vaccin
allergi
variabl
studi
show
iiv
contain
toler
ovalbumin
content
ml
develop
subunit
influenza
vaccin
often
compris
influenza
viru
ha
purifi
follow
protein
express
cell
could
mean
avoid
advers
reaction
peopl
egg
allergi
besid
subunit
vaccin
also
offer
desir
protect
season
influenza
virus
downsid
higher
dosag
requir
multipl
time
full
potenti
immun
protect
compar
elicit
wholeviru
vaccin
worth
note
laiv
iiv
cocktail
circul
season
influenza
virus
mainli
three
virus
ie
predetermin
domin
influenza
b
lineag
whether
yamagata
victoria
constitu
season
trival
influenza
vaccin
tiv
subunit
vaccin
also
formul
tiv
contain
ha
repres
vaccin
strain
howev
becam
necessari
featur
lineag
influenza
b
virus
base
current
global
epidemiolog
influenza
recommend
ambros
levin
result
advanc
quadrival
influenza
vaccin
qiv
contain
predetermin
repres
yamagata
victoria
influenza
b
viru
lineag
addit
two
predetermin
circul
season
influenza
subtyp
approach
vaccin
prepar
thu
requir
constant
reformul
maintain
desir
efficaci
limit
influenza
season
due
continu
burden
infect
influenza
us
cdc
advoc
use
season
influenza
vaccin
person
month
prior
winter
hand
extend
recommend
use
influenza
vaccin
person
categor
highrisk
compris
children
month
person
chronic
diseas
pregnant
women
healthcar
nurs
worker
howev
part
world
mostli
africa
asia
either
limit
establish
influenza
vaccin
polici
thu
restrict
avail
influenza
vaccin
make
vaccin
quit
uncommon
popul
perhap
vaccin
polici
might
consid
due
cost
acquir
vaccin
annual
still
reduc
efficaci
influenza
vaccin
critic
assess
xu
et
al
recommend
made
twicedos
vaccin
due
frequenc
season
influenza
occurr
year
round
although
poor
vaccin
coverag
african
countri
previous
report
duqu
et
al
upon
investig
avail
season
influenza
vaccin
still
clearli
underpin
core
reason
therefor
improv
efficaci
influenza
vaccin
would
also
contribut
enhanc
vaccin
coverag
africa
asia
rapid
influenza
viru
evolut
yearli
vaccin
reformul
make
stockpil
vaccin
futur
use
complic
issu
subsequ
delay
prepar
unforeseen
epidem
therefor
lot
research
focus
develop
novel
broadli
protect
vaccin
platform
hope
enhanc
immunogen
deliveri
consequ
immun
respons
select
antigen
platform
includ
viruslik
particl
vaccin
vlp
synthet
viru
vaccin
epitop
vaccin
antigenpres
cell
induc
vaccin
cobra
vaccin
nanoparticlebas
vaccin
viralvector
vaccin
tabl
viruslik
particl
noninfecti
multim
viral
surfac
glycoprotein
propens
selfassembl
vlp
design
maintain
nativ
viral
structur
without
complet
set
genet
materi
typic
influenza
vlp
ha
na
matrix
protein
typic
plasmid
construct
ha
na
use
transfect
cell
result
format
capsid
display
surfac
protein
ha
na
vlp
propos
effici
vaccin
rang
virus
includ
human
papilloma
viru
hpv
hepat
b
viru
hbv
hepat
e
viru
hev
discuss
zhao
et
al
although
exampl
complet
differ
biolog
compar
influenza
viru
rapid
advanc
need
new
vaccin
platform
gener
promis
data
influenza
vlp
instanc
overcom
challeng
rais
rapid
influenza
evolut
gao
et
al
attempt
gener
vlp
hbv
backbon
contain
matrix
protein
ectodomain
togeth
epitop
highli
conserv
nucleoprotein
np
mice
immun
chimer
vlp
induc
humor
well
cellmedi
immun
result
cross
protect
sever
strain
viru
anoth
approach
gener
vlp
via
combin
distinct
techniqu
describ
kapczynski
et
al
upon
coexpress
three
differ
clade
singl
na
protein
retrovir
gag
protein
manag
gener
tripleclad
vlp
shown
protect
chicken
lethal
challeng
heighten
immun
involv
innat
adapt
vlp
may
adjuv
variou
toll
like
receptor
tlr
ligand
demonstr
modifi
salmonella
flagellin
act
ligand
describ
wang
et
al
result
highli
specif
immunoglobulin
respons
also
gpianchor
incorpor
vlp
boost
iga
secret
cell
migrat
increas
murin
mucos
immun
drift
homolog
influenza
virus
well
longev
protect
vlp
thu
provid
platform
improv
formul
multival
contain
heterolog
epitop
influenza
vaccin
comput
optim
broadli
reactiv
antigen
vaccin
cobra
compris
vlp
carri
comput
design
ha
ted
ross
group
first
gener
consensu
amino
acid
ha
sequenc
clade
highli
pathogen
involv
human
infect
formul
vlp
express
ha
cobra
vlp
potent
induc
haneutr
antibodi
provid
effici
protect
immun
mice
ferret
pathogen
challeng
experi
similar
approach
also
demonstr
protect
cynomolgu
macaqu
abil
cobra
vlp
sinc
demonstr
power
system
induc
strong
broadli
neutral
antibodi
respons
multipl
clade
virus
multipl
isol
virus
similarli
develop
cobra
vaccin
also
shown
induc
broadli
neutral
antibodi
either
mice
ferret
broad
spectrum
virus
respect
sever
approach
tri
order
gener
attenu
virus
use
revers
genet
technolog
suggest
techniqu
downregul
viral
protein
synthesi
via
bias
viru
codon
sequenc
averag
codon
frequenc
alter
result
attenu
viru
mice
model
shown
fan
et
al
suggest
avian
vaccin
candid
fitter
egg
good
news
gener
influenza
vaccin
egg
altern
replicationincompet
virus
gener
upon
truncat
knockdown
nonstructur
viral
protein
notabl
inhibitor
hostprotect
interferoninduc
immun
led
phase
iii
clinic
trial
trival
vaccin
reveal
protect
vaccine
season
influenza
virus
platform
also
pave
way
gener
singlecycl
replic
influenza
virus
vaccin
candid
shown
similar
higher
protect
convent
laiv
main
reason
synthet
influenza
vaccin
remain
promis
due
abil
alter
viral
immunomodulatori
trait
amen
rapid
product
vaccin
epitopebas
vaccin
serv
immun
refocus
role
well
target
integr
viru
specif
epitop
remark
work
inspir
stabil
respiratori
syncyti
viru
fusion
protein
f
shown
rel
conserv
ha
stem
could
induc
broadli
neutral
antibodi
protect
mice
nonhuman
primat
sever
viru
subtyp
harbor
group
group
order
character
epitop
limit
variabl
locat
ha
head
thompson
et
al
observ
sera
collect
young
children
pandem
reveal
crossreact
pattern
histor
influenza
isol
conserv
epitop
situat
ha
head
confirm
demonstr
protect
capac
epitop
murin
challeng
divers
strain
influenza
anoth
univers
vaccin
candid
current
undergo
phase
iii
clinic
trial
base
escherichia
coliexpress
artifici
recombin
protein
consist
concaten
nine
linear
epitop
five
specif
ha
three
np
one
sever
influenza
viru
strain
vaccin
shown
induc
cellular
humor
immun
mice
envisag
abl
overcom
high
viru
mutat
rate
epitopebas
vaccin
therefor
afford
direct
involv
b
lymphocyt
requir
effectu
control
virus
infect
recent
focu
drawn
increas
abil
antigenpres
cell
apc
effici
involv
tcell
arm
immun
influenza
viru
clearanc
one
exampl
work
fonteneau
colleagu
show
exposur
influenza
viru
dendrit
cell
dc
dc
plasmacytoid
dc
induc
expans
antiinfluenza
viru
cytotox
lymphocyt
ctl
helper
cell
inspir
previou
find
abdelmot
et
al
also
demonstr
graft
alphag
epitop
onto
ha
promot
opson
therebi
enhanc
uptak
vaccin
viru
apc
importantli
work
et
al
show
possibl
target
ha
differ
surfac
molecul
antigen
present
cell
therebi
orient
immun
respons
toward
either
respons
cell
respons
varieti
approach
target
apc
includ
antibodi
nanoparticl
ligandmedi
method
emphas
apc
induc
vaccin
univers
continu
effort
develop
univers
influenza
vaccin
driven
use
selfassembl
monomer
ioncarri
molecul
call
ferritin
administr
multival
vaccin
construct
vivo
assess
nanoparticlebas
vaccin
display
multival
ha
divers
strain
influenza
virus
shown
induc
broadli
protect
antibodi
mice
whose
protect
span
strain
breadth
protect
nanoparticleinduc
antibodi
also
shown
profound
comparison
individu
compon
convent
multival
vaccin
tao
gill
also
immobil
matrix
protein
extracellular
domain
result
increas
induct
antibodi
afford
protect
mice
challeng
virul
strain
influenza
viru
intranas
administr
polylacticcoglycol
acid
plga
nanoparticl
conjug
influenza
conserv
peptid
vaccin
also
shown
induc
protect
lung
pig
via
induct
antigenspecif
cell
similar
approach
chahal
et
al
also
demonstr
induct
antibodi
respons
mice
separ
challeng
either
virus
ie
ebola
parasit
toxoplasma
gondii
immun
nanoparticl
formul
involv
singl
combin
genespecif
rna
encapsul
dendrim
recent
doublelay
protein
nanoparticl
develop
use
tandem
express
compris
human
avian
swine
domest
fowl
without
recombin
ha
stalk
protein
show
homosubtyp
heterosubtyp
protect
mice
immun
prior
challeng
specif
influenza
virus
though
promis
influenza
vaccin
platform
highthroughput
nanoparticlebas
vaccin
approach
facilit
replac
season
influenza
vaccin
still
develop
viralvector
vaccin
platform
design
mimic
natur
infect
viral
molecul
display
either
similar
dissimilar
viru
approach
shown
involv
humor
cellular
immun
use
modifi
vaccinia
viru
ankara
mva
vector
incorpor
influenza
np
protein
shown
potent
induct
influenza
virusspecif
humor
cellmedi
respons
lead
phase
ii
clinic
trial
adenoviru
vector
influenza
vaccin
equal
shown
strong
induct
influenza
viru
hastalk
crossreact
antibodi
mice
recent
lingel
et
al
express
multival
adenoviru
vector
influenza
viru
vaccin
compris
consensu
sequenc
diverg
demonstr
low
dose
administr
mice
confer
protect
mice
lethal
influenza
viru
challeng
experi
provid
avenu
scale
appropri
dose
later
use
season
vaccin
develop
effort
alphaviru
baculoviru
newcastl
diseas
viru
pox
viru
parainfluenza
viru
vesicular
stomat
viru
vector
also
propos
applic
vector
vaccin
manag
ongo
influenza
infect
current
requir
use
antivir
drug
two
drug
class
approv
control
influenza
infect
includ
adamantan
amantadin
rimantadin
na
inhibitor
oseltamivir
zanamivir
laninamivir
peramivir
wherea
adamantan
target
ion
channel
involv
releas
viral
ribonucleoprotein
complex
host
cell
na
inhibitor
act
competit
engag
viral
na
protein
otherwis
respons
newli
gener
virion
dissemin
howev
influenza
virus
resist
adamantan
neuraminidas
inhibitor
emerg
rapidli
show
need
search
either
novel
antivir
viral
host
target
use
develop
nextgener
drug
addit
lack
data
suggest
antivir
efficaci
highli
pathogen
avian
influenza
virus
hpai
ie
remain
import
issu
area
possibl
spillov
event
avian
human
imper
note
still
na
inhibitorsensit
influenza
virus
circul
drug
class
extrem
help
manag
outbreak
even
pandem
absenc
highli
efficaci
vaccin
burden
influenza
requir
identif
novel
compound
potenti
allevi
symptom
reduc
viral
shed
new
research
focus
develop
viru
target
antivir
also
one
target
host
organ
tabl
instanc
recombin
hostsial
acid
target
molecul
act
sialidas
surfac
host
suscept
cell
epitheli
cell
airway
inhibit
initi
attach
influenza
viru
ha
recogn
link
configur
sialic
acid
univers
due
abil
act
type
sialic
acid
therefor
use
host
shown
inhibit
virus
besid
influenza
virus
sialic
aciddepend
virus
human
metapneumoviru
parainfluenza
iii
viru
also
shown
inhibit
anoth
host
target
antivir
nitazoxanid
fall
categori
thiazolid
known
produc
activ
metabolit
follow
deacetyl
metabolit
shown
inhibit
matur
influenza
ha
block
traffick
insert
ha
onto
host
cell
surfac
nitazoxanid
licens
anthelminth
drug
repurpos
amelior
influenza
due
broad
rang
protect
effici
influenza
virus
phase
ii
biii
clinic
trial
antivir
pimodivir
nonnucleosid
influenza
viru
inhibitor
bind
conserv
domain
polymeras
subunit
influenza
virus
therebi
inhibit
host
capsnatch
perquisit
initi
viral
replic
pimodivir
shown
efficaci
nanomolar
concentr
prophylaxi
treatment
coadministr
neuraminidas
inhibitor
oseltamivir
mice
model
phase
ii
clinic
trial
also
confirm
efficaci
pimodivir
use
singl
drug
coadminist
oseltamivir
addit
drug
effect
associ
detect
interfer
cellular
process
current
ongo
recruit
phase
iii
intervent
trial
pimodivir
among
adolesc
adult
age
nonhospit
particip
chanc
develop
complic
meanwhil
preapprov
trial
pimodivir
treatment
patient
influenza
viru
infect
allow
furuta
et
al
discov
antiinfluenza
viru
drug
screen
antiinfluenza
compound
plaqu
reduct
assay
shown
select
index
influenza
virus
detect
cytotox
vitro
trial
mice
confirm
select
influenza
virus
protect
antiinfluenza
viru
therapeut
agent
along
line
furuta
colleagu
observ
inhibitori
action
drug
rna
virus
dna
virus
mechan
action
drug
attribut
inhibit
viral
rnadepend
rna
polymeras
activ
phosphoribosyl
act
nucleotid
analogu
henc
termin
viral
replic
warrant
experi
mani
rna
virus
possess
either
negativestrand
segment
rna
genom
arenaand
bunyavirus
positivestrand
rna
noro
flavivirus
summari
effect
influenza
virus
group
group
also
drugresist
strain
virus
exploit
treatment
virus
eg
ebola
viru
date
known
resist
report
except
purpos
mutat
confer
resist
laboratori
viru
strain
efficaci
treatment
influenza
thu
warrant
advanc
phase
iii
ii
trial
japan
us
respect
baloxavir
marboxil
anoth
antivir
first
develop
japan
shown
act
select
capdepend
endonucleas
inhibitor
influenza
virus
b
polymeras
subunit
pa
drug
exhibit
prefer
safeti
toler
pharmacokinet
properti
phase
trial
overal
optim
perform
uncompl
influenza
among
adult
adolesc
shown
phase
ii
iii
trial
involv
japanes
american
respect
drug
current
approv
market
us
xofluxa
treatment
acut
uncompl
influenza
among
year
arbidol
umifenovir
anoth
influenzalimit
drug
previous
licens
use
china
russia
almost
sever
decad
origin
develop
russia
found
potent
inhibit
influenza
viru
fusion
suscept
cell
membran
follow
interferon
induct
like
broadspectrum
antivir
discuss
earlier
besid
influenza
virus
arbidol
shown
effici
suppress
viral
infect
caus
paramyxovirus
picornavirus
bunya
virus
rhabdovirus
reovirus
togavirus
hepacivirus
ebola
viru
arenavirus
herpesvirus
flavivirus
zika
viru
west
nile
viru
tickborn
enceph
viru
current
phase
iii
trial
arbidol
ongo
china
drug
also
due
phase
iv
trial
unknown
statu
russia
ingavirin
drug
develop
russia
add
current
list
influenzalimit
antivir
due
direct
interfer
transport
newli
synthes
viral
np
ingavirin
approv
treatment
influenza
viral
caus
acut
respiratori
ill
russia
follow
complet
phase
iv
trial
need
new
strategi
control
influenza
infect
led
investig
antibodi
therapi
potenti
approach
base
neutral
monoclon
antibodi
mab
express
deliveri
host
pre
post
exposur
pathogen
figur
sever
clinic
trial
test
mab
efficaci
infecti
pathogen
includ
ibalizumab
success
approv
use
hivinfect
patient
palivizumab
treatment
respiratori
syncyti
viru
infect
feasibl
immunotherapi
rapidli
evolv
influenza
attain
upon
discoveri
broadli
neutral
antibodi
isol
mous
immun
antigen
character
show
bind
stem
ha
thu
provid
structur
basi
abil
inhibit
fusion
techniqu
fulli
recov
human
antibodi
improv
throsbi
et
al
use
human
memori
b
cell
phage
pan
recov
thirteen
mab
one
enter
clinic
trial
well
later
found
neutral
influenza
virus
group
ha
similarli
anoth
potenti
mab
inhibit
cleavag
also
isol
human
memori
b
cell
complet
phase
iia
clinic
trial
antibodi
neutral
virus
differ
phylogenet
group
also
overcom
amino
acid
chang
due
bind
flexibl
shown
xray
structur
follow
repertoir
broadli
neutral
antibodi
character
use
plasma
cell
discoveri
mab
crossneutr
multipl
viral
subtyp
could
lead
novel
passiv
immunotherapi
treatment
human
infect
could
also
potenti
abrog
spillov
infect
event
zoonot
speci
sever
exampl
antibodi
highest
potenti
use
manag
influenza
list
tabl
experi
lu
colleagu
demonstr
fragment
antigenbind
f
ab
region
equin
antibodi
could
protect
mice
lethal
challeng
influenza
exampl
show
use
passiv
immunotherapi
influenza
outbreak
could
complement
use
avail
antivir
would
increas
surviv
human
anim
antibodi
tend
elicit
antigen
variabl
head
domain
major
surfac
glycoprotein
ha
hand
less
variabl
stalk
domain
character
subimmunodomin
associ
minim
immun
respons
experi
margin
colleagu
employ
variabl
head
constant
stalk
domain
vaccin
mice
trigger
broadli
crossreact
stalkbas
antibodi
wohlbold
et
al
also
realiz
import
influenza
ha
stalk
good
vaccin
target
ascertain
transmissionblock
capac
stalkdirect
vaccin
ferret
addit
studi
el
bakkouri
et
al
use
immun
serum
mice
previous
immun
three
tandem
copi
fuse
hepat
b
viru
hbv
core
fusion
protein
show
fcdepend
immun
intranas
administr
monoclon
antina
antibodi
result
total
protect
mice
significantli
lower
viru
titer
viral
escap
determin
deep
sequenc
viral
genom
passiv
immunotherapi
demonstr
rapid
relief
lifesav
capabl
treatment
viral
infect
like
measl
rabi
hbv
other
establish
rsv
commerci
immunotherapi
palivizumab
antibodybas
therapi
influenza
antibodi
could
aid
suscept
popul
includ
infant
often
suffer
influenzarel
complic
consid
prophylact
use
antibodi
consid
part
immedi
manag
care
procedur
one
approach
consid
antibodi
deliveri
via
recombin
viru
vector
balaz
et
al
develop
adenoviralvector
human
broadli
neutral
antibodi
confer
protect
mice
receiv
construct
intramuscularli
pathogen
influenza
viru
challeng
experi
also
show
equal
protect
amount
intramuscularli
express
antibodi
sera
young
old
mice
nonobes
diabet
sever
combin
immunodeficiencyinterleukin
receptor
subunit
gamma
null
mice
suggest
efficaci
passiv
immunotherapi
could
age
immunodefici
antibodybas
immunoprophylaxi
therapeut
prospect
effect
intermedi
influenza
outbreak
product
specif
influenza
vaccin
note
broadlyreact
antibodi
capac
inhibit
viru
replic
shed
consolid
evid
passiv
immunotherapeut
manag
case
infect
describ
encount
rapid
relief
less
two
day
convalesc
plasma
administr
interestingli
result
detect
virus
realtim
polymeras
chain
reaction
furthermor
worth
note
divers
protect
mechan
antibodi
exert
function
directli
pathogen
pathogeninfect
cell
viru
neutral
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cell
phagocytosi
adcp
antibodydepend
cell
lysi
adcl
wellstudi
context
influenza
virus
adcc
mainli
involv
destruct
infect
cell
chiefli
natur
killer
nk
cell
activ
via
perforin
granzym
b
secret
infect
cell
lead
cell
lysi
destruct
intracellular
pathogen
via
recognit
antibodi
fc
crosslink
nk
cell
fc
receptor
fcr
observ
murin
antibodi
weakli
interact
cognat
influenza
similarli
viru
replic
mice
shown
suppress
due
neutrophilantibodi
base
enhanc
phagocytosi
adcp
pulmonari
infect
mice
either
receiv
antiinfluenza
serum
influenza
infect
neutrophil
retain
inhibit
antibodi
direct
viru
neutral
antibodi
bind
receptorbind
site
nearbi
site
hemagglutinin
prevent
viral
attach
host
cell
antibodi
mainli
target
globular
head
ha
elicit
either
vaccin
natur
infect
adcl
anoth
mechan
could
augment
kill
influenza
virus
observ
terajima
et
al
realiz
mostli
neutral
human
monoclon
antibodi
either
recogn
globular
head
stalk
ha
exert
kind
effect
contrari
previous
associ
stalkspecif
antibodi
emphas
therapeut
capac
novel
monoclon
antibodi
combat
influenza
infect
specul
addit
use
effect
antivir
passiv
immunotherapi
influenza
b
virus
might
way
forward
influenza
viru
manag
amongst
class
high
lowrisk
patient
envisag
involv
passiv
immun
culmin
acceler
relief
mechan
previous
describ
provid
allow
time
full
activ
adapt
immun
system
via
convent
antigenpres
mechan
addit
infect
person
passiv
immun
could
develop
natur
immun
specif
virus
immun
could
longlast
give
protect
antigenicallymatch
strain
also
associ
passiv
immun
rapid
relief
increas
chanc
abat
evolut
escap
mutant
suggest
aris
due
vaccin
consequ
herd
immun
improv
vaccin
deliveri
efficaci
paramount
combat
continu
circul
epidem
influenza
howev
addit
ongo
deploy
novel
antivir
strategi
includ
highli
promis
immun
therapi
treatment
prophylaxi
vital
limit
protect
ongo
threat
pandem
influenza
